Across 224 lymphoma Phase II and III trials authorized from 2024 to 2026, site activity is concentrated in large academic hematology networks. University Hospital Cologne was the most repeatedly appearing site, while France, Italy, Germany, Spain, and the Netherlands formed the largest country-level recruitment and site-allocation backbone.
The leading lymphoma trial sites were mostly university hospitals or national hematology centers. University Hospital Cologne appeared in 8 lymphoma Phase II/III trial site lists, followed by Rigshospitalet, Medical University of Vienna, and Centre Hospitalier Universitaire de Bordeaux with 7 appearances each.
The top site list is not dominated by one country alone. It reflects a pan-European lymphoma infrastructure built around repeat hematology investigators, national cooperative networks, and academic centers with capacity for complex systemic therapy trials.
Phase II trials accounted for 151 of 224 lymphoma trials, or 67.4%. Phase III trials accounted for 73 of 224 trials, or 32.6%. The phase mix indicates that much of the lymphoma site network is being used for signal-seeking or expansion-stage development rather than only confirmatory studies.
For sponsors, the operational competition is likely felt earlier than Phase III. Sites that repeatedly appear in Phase II lymphoma trials are important strategic partners because they may later become anchors for confirmatory programs.
France, Italy, Germany, Spain, and the Netherlands formed the largest country-level allocation group. Together, these five countries accounted for 4,030 planned participants in the reviewed lymphoma Phase II/III geography records.
Patient allocation follows mature hematology-trial ecosystems rather than population size alone. Italy and France combine broad site networks with high planned enrollment, while Germany and Spain provide repeated academic-hospital participation across both Phase II and Phase III.
B-cell and non-Hodgkin lymphoma categories accounted for 151 of 224 trials, or 67.4%. Hodgkin lymphoma represented 29 trials, or 12.9%, while T-cell lymphoma represented 18 trials, or 8.0%. Mixed or broader lymphoma records accounted for the remaining 26 trials, or 11.6%.
The site network is primarily shaped by B-cell lymphoma development, including DLBCL, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, CLL/SLL, and broader non-Hodgkin lymphoma categories. This helps explain why large hematology centers with cell therapy, antibody, and combination-regimen capacity appear repeatedly.
European lymphoma Phase II/III trial activity is concentrated around repeat hematology centers rather than evenly distributed across all oncology sites. The strongest operational hubs are university hospitals and national cancer or hematology institutions in Germany, France, Italy, Spain, the Netherlands, Austria, and Denmark.
For lymphoma development teams, site selection should prioritize proven repeat-participation hematology centers, but country planning should not rely only on the single highest-volume site. The data point to a distributed hub model: multiple high-performing centers per country, especially in France, Italy, Germany, Spain, and the Netherlands.